LP352

DRUG5 trials

Sponsors

Longboard Pharmaceuticals

Conditions

Developmental and Epileptic EncephalopathiesDevelopmental and Epileptic EncephalopathyDravet SyndromeLennox Gastaut Syndrome

Phase 1

Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

CompletedNCT05364021

Longboard PharmaceuticalsDevelopmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox Gastaut Syndrome

Start: 2022-03-03End: 2023-11-20Updated: 2024-11-08

Phase 3

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

Active, not recruitingNCT06660394

Longboard PharmaceuticalsDravet Syndrome

Start: 2024-09-25End: 2026-12-31Updated: 2026-09-17

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

Active, not recruitingNCT06719141

Longboard PharmaceuticalsDevelopmental and Epileptic Encephalopathy

Start: 2024-11-11End: 2026-11-30Updated: 2026-09-15

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

Enrolling by invitationNCT06908226

Longboard PharmaceuticalsDevelopmental and Epileptic Encephalopathy

Start: 2025-02-12End: 2027-12-17Target: 324Updated: 2026-09-15

Unknown Phase

Intermediate-Size Expanded Access Protocol (EAP) for LP352

Longboard PharmaceuticalsDevelopmental and Epileptic Encephalopathies, Dravet Syndrome, Lennox Gastaut Syndrome

Updated: 2025-01-22